Artiva Biotherapeutics, Inc. ARTV 深 滬
已收盤 12-05 16:00:00 美东时间
3.36
-0.415
-10.99%
華盛通- 最 高3.80
- 今 開3.80
- 成交量 14.29万股
- 最 低 3.32
- 昨 收 3.775
- 總市值 8247.09万
- 52周最高 11.55
- 市盈率 靜 --
- 換手率 0.58%
- 52周最低 1.47
- 委 比 17.84%
- 總股本 2454.49万
- 歷史最高 17.31
- 量 比 1.65
- 振 幅 12.72%
- 歷史最低 1.47
- 每 手 1
- 風險率 2.58%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 富国银行上调AMD目标价升至345美元；花旗上调礼来目标价升至1500美元；巴克莱上调腾讯音乐目标价升至28美元
今日重点评级关注：HC Wainwright & Co.：维持Artiva Biotherapeutics"买入"评级，目标价从12美元升至15美元；Canaccord Genuity：维持Viking Therapeutics"买入"评级，目标价从106美元升至107美元
11-13 09:58
Artiva Biotherapeutics Showcases AlloNK As First Off-The-Shelf NK Cell Therapy Demonstrating Deep B-Cell Depletion With Favorable Tolerability Profile
32 patients with autoimmune disease treated with AlloNK plus anti-CD20 monoclonal antibody (mAb) as of October 1, 2025, data cutoffAll patients received AlloNK as outpatients, and the majority were treated in community
11-12 20:25
Artiva Biotherapeutics To Host Event For Discussing Safety, Translational Data For AlloNK In Combination With Anti-cd20 Antibodies Across Autoimmune Diseases
Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and
11-04 05:19
美股大行评级 | 潜在最高涨幅37.45%，甲骨文获多家机构上调目标价；瑞穗上调美光科技目标价升至240美元
今日重点评级关注：韦德布什：维持Artiva Biotherapeutics"跑赢大市"评级，目标价从18美元升至23美元；巴克莱：维持Cellectis"超配"评级，目标价从4美元升至8美元
10-20 10:03
Why Is Artiva Up Today?
Shares of Artiva Biotherapeutics, Inc. are rising Friday after the San Diego-based biotech company shared a milestone regulatory update.
10-18 03:07
Market-Moving News for October 17th
CSX: 3% | CSX shares are trading higher after the company reported better-than-expected Q3 financial results. ARTV: 144% | Artiva Biotherapeutics Receives FDA Fast Track Designation For AlloNK; Continued
10-17 19:27
Artiva Biotherapeutics Receives FDA Fast Track Designation For AlloNK; Continued Execution And Enrollment Progress With More Than 20 Patients Treated With AlloNK + Monoclonal Antibody Therapy Across Company-sponsored And Investigator-Initiated Trials In Autoimmune Diseases
SAN DIEGO, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for
10-17 04:08
Artiva Biotherapeutics Announces Refractory Rheumatoid Arthritis as Lead Indication, Upcoming Data Releases, and Corporate Update
Artiva Biotherapeutics received FDA Fast Track Designation for AlloNK® in refractory rheumatoid arthritis (RA), making it the first drug candidate in the deep B-cell depleting category to receive this designation. Over 20 patients have been treated with AlloNK + monoclonal antibody therapy across various autoimmune diseases. The company plans to release translational and safety data in mid-November, highlighting deep B-cell depletion and favorabl...
10-16 20:05
Artiva Biotherapeutics Reports Progress in Clinical Trials
Artiva Biotherapeutics, Inc. ( ($ARTV) ) has released its Q2 earnings. Here is ...
08-29 12:10
